| Literature DB >> 29466423 |
Gabriel Velez1,2,3, Daniel A Machlab1, Peter H Tang1,2,4, Yang Sun2,4, Stephen H Tsang5,6, Alexander G Bassuk7, Vinit B Mahajan1,2,4.
Abstract
Differences in regional protein expression within the human retina may explain molecular predisposition of specific regions to ophthalmic diseases like age-related macular degeneration, cystoid macular edema, retinitis pigmentosa, and diabetic retinopathy. To quantify protein levels in the human retina and identify patterns of differentially-expressed proteins, we collected foveomacular, juxta-macular, and peripheral retina punch biopsies from healthy donor eyes and analyzed protein content by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Protein expression was analyzed with 1-way ANOVA, gene ontology, pathway representation, and network analysis. We identified a mean of 1,974 proteins in the foveomacular retina, 1,999 in the juxta-macular retina, and 1,779 in the peripheral retina. Six hundred ninety-seven differentially-expressed proteins included those unique to and abundant in each anatomic region. Proteins with higher expression in each region include: heat-shock protein 90-alpha (HSP90AA1), and pyruvate kinase (PKM) in the foveomacular retina; vimentin (VIM) and fructose-bisphosphate aldolase C (ALDOC); and guanine nucleotide-binding protein subunit beta-1 (GNB1) and guanine nucleotide-binding protein subunit alpha-1 (GNAT1) in the peripheral retina. Pathway analysis identified downstream mediators of the integrin signaling pathway to be highly represented in the foveomacular region (P = 6.48 e-06). Metabolic pathways were differentially expressed among all retinal regions. Gene ontology analysis showed that proteins related to antioxidant activity were higher in the juxta-macular and the peripheral retina, but present in lower amounts in the foveomacular retina. Our proteomic analysis suggests that certain retinal regions are susceptible to different forms of metabolic and oxidative stress. The findings give mechanistic insight into retina function, reveal important molecular processes, and prioritize new pathways for therapeutic targeting.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29466423 PMCID: PMC5821407 DOI: 10.1371/journal.pone.0193250
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Global analysis of retinal regions.
(A) Punch biopsy dissection of human retinal regions for proteomic analysis: foveomacular (FM), juxta-macular (JM), and peripheral retina (P). (B) Proteins were identified using LC-MS/MS with spectral counts of ≤ 2 were used for further bioinformatics analysis. Venn diagram shows that 1354 proteins are shared among all three regions.
Fig 2Hierarchical clustering of differentially-expressed proteins in retinal regions.
Protein spectral counts were analyzed with 1-way ANOVA and hierarchical heatmap clustering. Results are represented as a heatmap and display protein expression levels on a logarithmic scale. Orange indicates high expression while dark green/black indicates low or no expression. A total of 697 proteins were differentially-expressed among the three groups (p < 0.05). Of these proteins, 484 were highly-expressed in the foveomacular retina. A total of 213 proteins were significantly elevated in the periphery. There was a blend of protein expression in the juxta-macular retina.
Fig 3Gene ontology distributions of retina regions highlight tissue differences.
(A) Differentially-expressed proteins from the foveomacular, juxta-macular, and peripheral retina. Gene ontology analysis categorized each protein group by biological process, molecular function, and cellular compartment. (B) Top pathways represented in the three retina regions. Pathways are ranked by their log (p-value), obtained from the right-tailed Fisher Exact Test.
Differentially-expressed proteins related to retinal diseases.
Our proteomics dataset was interrogated for the presence of retinal disease biomarkers. Spectral count levels are organized by retinal region.
| Protein | Associated Diseases | Protein Level (Average Spectra Count ± SD) | ||
|---|---|---|---|---|
| Foveomacular | Juxta-macular | Peripheral | ||
| SAG | Recessive Oguchi disease; recessive retinitis pigmentosa | 418 ± 9 | 537 ± 25 | 672 ± 98 |
| RLBP1 | Recessive retinitis pigmentosa; recessive Bothnia dystrophy; recessive retinitis punctata albescens; recessive Newfoundland rod-cone dystrophy | 329 ± 39 | 393 ± 6 | 469 ± 62 |
| GNAT1 | Dominant congenital stationary night blindness, Nougaret type; recessive congenital stationary night blindness | 290 ± 41 | 447 ± 36 | 494 ± 59 |
| RHO | Dominant retinitis pigmentosa; dominant congenital stationary night blindness; recessive retinitis pigmentosa | 236 ± 43 | 363 ± 51 | 358 ± 41 |
| PDE6C | Recessive cone dystrophy, early onset; recessive complete and incomplete achromatopsia | 14 ± 7 | 8 ± 5 | 1 ± 2 |
| CNGB1 | Recessive retinitis pigmentosa | 18 ± 5 | 38 ± 3 | 44 ± 6 |
| BSG | Impaired retinal function in a mouse model | 93 ± 9 | 87 ± 7 | 74 ± 6 |
| RGR | Recessive retinitis pigmentosa; dominant choroidal sclerosis; protein | 7 ± 5 | 8 ± 2 | 3 ± 5 |
| RS1 | Retinoschisis | 55 ± 10 | 45 ± 14 | 35 ± 3 |
| VWF | Age-related macular degeneration | 6 ± 2 | 5 ± 1 | 0 ± 0 |
Fig 4Differential expression of metabolic and antioxidant stress proteins highlights drug repositioning opportunities for retinal disease.
Pathway diagram of metabolic and antioxidant proteins with high representation in the human retina. Each pie chart represents the relative protein representation in the foveomacular (orange), juxta-macular (blue), and peripheral retina (purple). Proteins are organized by their molecular pathway and respective metabolites. Compounds and mimetic drugs targeting these specific proteins and metabolites (light blue) are listed in the metabolic map (red). HK2 indicates hexokinase-2; ALDOA, aldolase A; ALDOC, aldolase C; PGAM1, phosphoglycerate mutase 1; PGAM4, phosphoglycerate mutase 4; LDHB, lactate dehydrogenase B; LDHC, lactate dehydrogenase C; LDHAL6H, lactate dehydrogenase A-like 6H; PKM, pyruvate kinase; PDHE1, pyruvate dehydrogenase E1 component subunit alpha; TALDO1, transaldolase; GPX3, glutathione peroxidase 3; CAT, catalase; SOD1, superoxide dismutase 1; PRDX1, peroxiredoxin 1; PRDX4, peroxiredoxin 4; PRDX6, peroxiredoxin 6; CS, citrate synthase; ACO2, aconitate hydratase 2; CYTC, cytochrome c; NDUFS8, NADH dehydrogenase [ubiquinone] iron-sulfur protein 8; NDUFB7, NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7; NDUFV2, NADH dehydrogenase [ubiquinone] flavoprotein 2; NDUFA7, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7; MT-ND5, NADH-ubiquinone oxidoreductase chain 5; COX5A, cytochrome c oxidase subunit 5A; COX5B, cytochrome c oxidase subunit 5B; COX4I1, cytochrome c oxidase subunit 4 isoform 1; COX6B1, cytochrome c oxidase subunit 6B1; MT-CO2, cytochrome c oxidase subunit 2; UQCRC1, Cytochrome b-c1 complex subunit 1.